Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

Journal for immunotherapy of cancer·2026

Same author

A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.

Liver cancer·2026

Same author

Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.

The oncologist·2026

Same author

Prolonged response to dual immune checkpoint blockade in patients with advanced solid tumors: a case series.

NPJ precision oncology·2025

Same author

Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit.

Cancer research communications·2025

Same author

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same journal

Retraction: Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression.

Oncotarget·2026

Same journal

TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer.

Oncotarget·2026

Same journal

Retraction: MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.

Oncotarget·2026

Same journal

Laryngeal leiomyosarcoma: A rare case report and literature review.

Oncotarget·2026

Same journal

Correction: Postsurgery fluids promote transition of cancer stem cell toendothelial and AKT/mTOR activity contributing to relapse of giant cell tumors of bone.

Oncotarget·2026

Same journal

DHHC3 interferes with antitumor immunity in melanoma cells.

Oncotarget·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 4, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.

Filip Janku¹, Bart Claes², Helen J Huang¹

¹Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

|September 3, 2015

Summary

This summary is machine-generated.

The Idylla BRAF Mutation Test offers a rapid and accurate method for detecting BRAF V600 mutations in cancer diagnostics. This novel test demonstrates high concordance with existing methods, improving precision therapy implementation.

Keywords:

BRAF integrated qPCR rapid

More Related Videos

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

Rapid and Efficient Zebrafish Genotyping Using PCR with High-resolution Melt Analysis

Rapid and Efficient Zebrafish Genotyping Using PCR with High-resolution Melt Analysis

Published on: February 5, 2014

Related Experiment Videos

Last Updated: Apr 4, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

Rapid and Efficient Zebrafish Genotyping Using PCR with High-resolution Melt Analysis

Rapid and Efficient Zebrafish Genotyping Using PCR with High-resolution Melt Analysis

Published on: February 5, 2014

Area of Science:

Oncology
Molecular Diagnostics
Cancer Genomics

Background:

Precision therapy for BRAF-mutant cancers requires fast and accurate diagnostic tools.
Current methods for BRAF V600 mutation detection can be time-consuming and complex.
There is a need for improved diagnostic systems to facilitate timely treatment decisions.

Purpose of the Study:

To evaluate the performance of the novel Idylla BRAF Mutation Test.
To compare the Idylla test's accuracy and speed against established BRAF V600 mutation detection methods.
To assess the utility of the Idylla test for analyzing formalin-fixed paraffin-embedded (FFPE) tumor samples.

Main Methods:

The Idylla BRAF Mutation Test was used to detect BRAF V600 mutations in archived FFPE tumor samples.
Results were compared with the cobas 4800 BRAF V600 Mutation Test, MiSeq deep sequencing, and CLIA-certified laboratory methods (PCR, mass spectrometry, NGS).
Two sets of FFPE samples (60 and 100 samples) were analyzed to assess test concordance and performance.

Main Results:

The Idylla test showed high agreement with cobas (97%) and CLIA-certified laboratory methods (96%).
100% concordance was observed between the Idylla test and MiSeq deep sequencing.
The Idylla test provided rapid results (approx. 90 minutes sample-to-result time) with minimal hands-on time (approx. 2 minutes).
The closed cartridge system of the Idylla test minimizes the risk of PCR contamination.

Conclusions:

The Idylla BRAF Mutation Test is a rapid and highly accurate diagnostic tool for BRAF V600 mutation detection.
The test demonstrates excellent concordance with existing, more complex diagnostic methods.
Idylla offers a valuable alternative for BRAF mutation testing, supporting the implementation of precision oncology.